|
1
|
Ting AH, McGarvey KM and Baylin SB: The
cancer epigenome - components and functional correlates. Genes Dev.
20:3215–3231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choi JD and Lee JS: Interplay between
epigenetics and genetics in cancer. Genomics Inf. 11:164–173. 2013.
View Article : Google Scholar
|
|
3
|
Flis S, Gnyszka A and Flis K: DNA
methyltransferase inhibitors improve the effect of chemotherapeutic
agents in SW48 and HT-29 colorectal cancer cells. PLoS One.
27:e923052014. View Article : Google Scholar
|
|
4
|
Geurts van Kessel A: The cancer genome:
from structure to function. Cell Oncol. 37:155–165. 2014.
View Article : Google Scholar
|
|
5
|
Tallen G and Riabowol K: Keep-ING balance:
Tumor suppression by epigenetic regulation. FEBS Lett.
588:2728–2742. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wee S, Dhanak D, Li H, Armstrong SA,
Copeland RA, Sims R, Baylin SB, Liu XS and Schweizer L: Targeting
epigenetic regulators for cancer therapy. Ann NY Acad Sci.
1309:30–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jeong HM, Kwon MJ and Shin YK:
Overexpression of cancer-associated genes via epigenetic
derepression mechanisms in gynecologic cancer. Front Oncol.
4:122014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Subramaniam D, Thombre R, Dhar A and Anant
S: DNA methyltransferases: A novel target for prevention and
therapy. Front Oncol. 4:802014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Campbell RM and Tummino PJ: Cancer
epigenetics drug discovery and development: The challenge of
hitting the mark. J Clin Invest. 124:64–69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cantley MD and Haynes DR: Epigenetic
regulation of inflammation: Progressing from broad acting histone
deacetylase (HDAC) inhibitors to targeting specific HDACs.
Inflammopharmacology. 21:301–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Henning SM, Wang P, Carpenter CL and Heber
D: Epigenetic effects of green tea polyphenols in cancer.
Epigenomics. 5:729–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang P, He X and Malhotra A: Epigenetic
targets of polyphenols in cancer. J Environ Pathol Toxicol Oncol.
33:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharma C, Nusri Q-A, Begum S, Javed E,
Rizvi TA and Hussain A: (−)-Epigallocatechin-3-gallate induces
apoptosis and inhibits invasion and migration of human cervical
cancer cells. Asian Pac J Cancer Prev. 13:4815–4822. 2012.
View Article : Google Scholar
|
|
14
|
Lin CH, Chao LK, Hung PH and Chen YJ: EGCG
inhibits the growth and tumorigenicity of nasopharyngeal
tumor-initiating cells through attenuation of STAT3 activation. Int
J Clin Exp Pathol. 7:2372–2381. 2014.PubMed/NCBI
|
|
15
|
Siddiqui IA, Bharali DJ, Nihal M, Adhami
VM, Khan N, Chamcheu JC, Khan MI, Shabana S, Mousa SA and Mukhtar
H: Excellent anti-proliferative and pro-apoptotic effects of
(−)-epigallocatechin-3-gallate encapsulated in chitosan
nanoparticles on human melanoma cell growth both in vitro and in
vivo. Nanomedicine. 10:1619–1626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo HQ, Xu M, Zhong WT, Cui ZY, Liu FM,
Zhou KY and Li XY: EGCG decreases the expression of HIF-1α and VEGF
and cell growth in MCF-7 breast cancer cells. J BUON. 19:435–439.
2014.PubMed/NCBI
|
|
17
|
Butt MS, Ahmad RS, Sultan MT, Nasir Qayyum
MM and Naz A: Green tea and anticancer perspectives: Updates from
last decade. Crit Rev Food Sci Nutr. 55:792–805. 2015. View Article : Google Scholar
|
|
18
|
Yokoyama M, Noguchi M, Nakao Y, Ysunaga M,
Yamasaki F and Iwasaka T: Antiproliferative effects of the major
tea polyphenol, (−)-epigallocatechin gallate and retinoic acid in
cervical adenocarcinoma. Gynecol Oncol. 108:326–331. 2008.
View Article : Google Scholar
|
|
19
|
Millard CJ, Watson PJ, Celardo I,
Gordiyenko Y, Cowley SM, Robinson CV, Fairall L and Schwabe JW:
Class I HDACs share a common mechanism of regulation by inositol
phosphates. Mol Cell. 51:57–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia D, Jurkowska RZ, Zhang X, Jeltsch A
and Cheng X: Structure of Dnmt3a bound to Dnmt3L suggests a model
for de novo DNA methylation. Nature. 449:248–251. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thangapandian S, John S, Lee Y,
Arulalapperumal V and Lee KW: Molecular modeling study on tunnel
behavior in different histone deacetylase isoforms. PLoS One.
7:e493272012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Irwin JJ, Sterling T, Mysinger MM, Bolstad
ES and Coleman RG: ZINC: A free tool to discover chemistry for
biology. J Chem Inf Model. 52:1757–1768. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grosdidier A, Zoete V and Michielin O:
SwissDock, a protein-small molecule docking web service based on
EADock DSS. Nucleic Acids Res. 39:W270–W277. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pettersen EF, Goddard TD, Huang CC, Couch
GS, Greenblatt DM, Meng EC and Ferrin TE: UCSF Chimera - a
visualization system for exploratory research and analysis. J
Comput Chem. 25:1605–1612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El-Shakankiry NH and Mossallam GI: p15
(INK4B) and E-cadherin CpG island methylation is frequent in
Egyptian acute myeloid leukemia. J Egypt Natl Canc Inst.
18:227–232. 2006.
|
|
26
|
Suzuki M, Shigematsu H, Iizasa T,
Hiroshima K, Nakatani Y, Minna JD, Gazdar AF and Fujisawa T:
Exclusive mutation in epidermal growth factor receptor gene, HER-2,
and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Cancer. 106:2200–2207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yaqinuddin A, Qureshi SA, Qazi R and Abbas
F: Down-regulation of DNMT3b in PC3 cells effects locus-specific
DNA methylation, and represses cellular growth and migration.
Cancer Cell Int. 8:132008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saito Y, Kanai Y, Sakamoto M, Saito H,
Ishii H and Hirohashi S: Overexpression of a splice variant of DNA
methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation
on pericentromeric satellite regions during human
hepatocarcinogenesis. Proc Natl Acad Sci USA. 99:10060–10065. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goelden U, Ukena SN, Pfoertner S, Hofmann
R, Buer J and Schrader AJ: RAR-beta(1) overexpression in
chromophobe renal cell carcinoma: A novel target for therapeutic
intervention? Exp Oncol. 27:220–224. 2005.PubMed/NCBI
|
|
30
|
Wang AG, Kim SU, Lee SH, Kim SK, Seo SB,
Yu DY and Lee DS: Histone deacetylase 1 contributes to cell cycle
and apoptosis. Biol Pharm Bull. 28:1966–1970. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jin Y, Blue EK and Gallagher PJ: Control
of death-associated protein kinase (DAPK) activity by
phosphorylation and proteasomal degradation. J Biol Chem.
281:39033–39040. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang J, Nicolau MM, Cox TR, Wetterskog D,
Martens JW, Barker HE and Erler JT: LOXL2 induces aberrant acinar
morphogenesis via ErbB2 signaling. Breast Cancer Res. 15:R672013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Capobianco E, Mora A, La Sala D, Roberti
A, Zaki N, Badidi E, Taranta M and Cinti C: Separate and combined
effects of DNMT and HDAC inhibitors in treating human multi-drug
resistant osteosarcoma HosDXR150 cell line. PLoS One. 9:e955962014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Al-Rayyan N, Litchfield LM, Ivanova MM,
Radde BN, Cheng A, Elbedewy A and Klinge CM: 5-Aza-2-deoxycytidine
and trichostatin A increase COUP-TFII expression in
antiestrogen-resistant breast cancer cell lines. Cancer Lett.
347:139–150. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thakur VS, Deb G, Babcook MA and Gupta S:
Plant phytochemicals as epigenetic modulators: Role in cancer
chemoprevention. AAPS J. 16:151–163. 2014. View Article : Google Scholar :
|
|
36
|
Jiao F, Wang X, Yan Z, Liu C, Yue Z, Li Z,
Ma Y, Li Y and Wang J: Effect of dynamic DNA methylation and
histone acetylation on cPouV expression in differentiation of chick
embryonic germ cells. Stem Cells Dev. 22:2725–2735. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Herranz M and Esteller M: DNA methylation
and histone modifications in patients with cancer: Potential
prognostic and therapeutic targets. Methods Mol Biol. 361:25–62.
2007.
|
|
38
|
Oyer JA, Chu A, Brar S and Turker MS:
Aberrant epigenetic silencing is triggered by a transient reduction
in gene expression. PLoS One. 4:e48322009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zopf S, Ocker M, Neureiter D, Alinger B,
Gahr S, Neurath MF and Di Fazio P: Inhibition of DNA
methyltransferase activity and expression by treatment with the
pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma
cell lines. BMC Cancer. 12:3862012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu WG and Otterson GA: The interaction of
histone deacetylase inhibitors and DNA methyltransferase inhibitors
in the treatment of human cancer cells. Curr Med Chem Anticancer
Agents. 3:187–199. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vendetti FP and Rudin CM: Epigenetic
therapy in non-small-cell lung cancer: Targeting DNA
methyltransferases and histone deacetylases. Expert Opin Biol Ther.
13:1273–1285. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ben Gacem R, Hachana M, Ziadi S, Ben
Abdelkarim S, Hidar S and Trimeche M: Clinicopathologic
significance of DNA methyltransferase 1, 3a, and 3b overexpression
in Tunisian breast cancers. Hum Pathol. 43:1731–1738. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Girault I, Tozlu S, Lidereau R and Bièche
I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in
sporadic breast carcinomas. Clin Cancer Res. 9:4415–4422.
2003.PubMed/NCBI
|
|
44
|
Mizuno S, Chijiwa T, Okamura T, Akashi K,
Fukumaki Y, Niho Y and Sasaki H: Expression of DNA
methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in
acute and chronic myelogenous leukemia. Blood. 97:1172–1179. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qu Y, Mu G, Wu Y, Dai X, Zhou F, Xu X,
Wang Y and Wei F: Overexpression of DNA methyltransferases 1, 3a,
and 3b significantly correlates with retinoblastoma tumorigenesis.
Am J Clin Pathol. 134:826–834. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Müller BM, Jana L, Kasajima A, Lehmann A,
Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W and Denkert
C: Differential expression of histone deacetylases HDAC1, 2 and 3
in human breast cancer - overexpression of HDAC2 and HDAC3 is
associated with clinicopathological indicators of disease
progression. BMC Cancer. 13:2152013. View Article : Google Scholar :
|
|
47
|
Santoro F, Botrugno OA, Dal Zuffo R, et
al: A dual role for Hdac1: Oncosuppressor in tumorigenesis,
oncogene in tumor maintenance. Blood. 121:3459–3468. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang H, Salz T, Zajac-Kaye M, Liao D,
Huang S and Qiu Y: Overexpression of histone deacetylases in cancer
cells is controlled by interplay of transcription factors and
epigenetic modulators. FASEB J. 28:4265–4279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fazi F, Travaglini L, Carotti D, et al:
Retinoic acid targets DNA-methyltransferases and histone
deacetylases during APL blast differentiation in vitro and in vivo.
Oncogene. 24:1820–1830. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shu L, Khor TO, Lee JH, Boyanapalli SS,
Huang Y, Wu TY, Saw CL, Cheung KL and Kong AN: Epigenetic CpG
demethylation of the promoter and reactivation of the expression of
Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 13:606–614.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Moseley VR, Morris J, Knackstedt RW and
Wargovich MJ: Green tea polyphenol epigallocatechin 3-gallate,
contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human
colon cancer cells. Anticancer Res. 33:5325–5333. 2013.PubMed/NCBI
|
|
52
|
Fan H, Zhang R, Tesfaye D, Tholen E, Looft
C, Hölker M, Schellander K and Cinar MU: Sulforaphane causes a
major epigenetic repression of myostatin in porcine satellite
cells. Epigenetics. 7:1379–1390. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H,
Welsh W and Yang CS: Tea polyphenol (−)-epigallocatechin-3-gallate
inhibits DNA methyltransferase and reactivates methylation-silenced
genes in cancer cell lines. Cancer Res. 63:7563–7570.
2003.PubMed/NCBI
|
|
54
|
Lee WJ, Shim JY and Zhu BT: Mechanisms for
the inhibition of DNA methyltransferases by tea catechins and
bioflavonoids. Mol Pharmacol. 68:1018–1030. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kuck D, Caulfield T, Lyko F and
Medina-Franco JL: Nanaomycin A selectively inhibits DNMT3B and
reactivates silenced tumor suppressor genes in human cancer cells.
Mol Cancer Ther. 9:3015–3023. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Caulfield T and Medina-Franco JL:
Molecular dynamics simulations of human DNA methyltransferase 3B
with selective inhibitor nanaomycin A. J Struct Biol. 176:185–191.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Akhavan-Niaki H and Samadani AA: DNA
methylation and cancer development: Molecular mechanism. Cell
Biochem Biophys. 67:501–513. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gokul G and Khosla S: DNA methylation and
cancer. Subcell Biochem. 61:597–625. 2013. View Article : Google Scholar
|
|
59
|
Shu XS, Li L and Tao Q: Chromatin
regulators with tumor suppressor properties and their alterations
in human cancers. Epigenomics. 4:537–549. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Narayan G, Arias-Pulido H, Koul S, Vargas
H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M and
Murty VV: Frequent promoter methylation of CDH1, DAPK, RARB, and
HIC1 genes in carcinoma of cervix uteri: Its relationship to
clinical outcome. Mol Cancer. 2:242003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kang S, Kim JW, Kang GH, Lee S, Park NH,
Song YS, Park SY, Kang SB and Lee HP: Comparison of DNA
hypermethylation patterns in different types of uterine cancer:
Cervical squamous cell carcinoma, cervical adenocarcinoma and
endometrial adenocarcinoma. Int J Cancer. 118:2168–2171. 2006.
View Article : Google Scholar
|
|
62
|
Braggio E, Maiolino A, Gouveia ME,
Magalhães R, Souto Filho JT, Garnica M, Nucci M and Renault IZ:
Methylation status of nine tumor suppressor genes in multiple
myeloma. Int J Hematol. 91:87–96. 2010. View Article : Google Scholar
|
|
63
|
Liu S, Ren S, Howell P, Fodstad O and
Riker AI: Identification of novel epigenetically modified genes in
human melanoma via promoter methylation gene profiling. Pigment
Cell Melanoma Res. 21:545–558. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X,
Shi DR, Wang P, Yang ZH and Zhu JD: Methylation profile of the
promoter CpG islands of 31 genes that may contribute to colorectal
carcinogenesis. World J Gastroenterol. 10:3441–3454.
2004.PubMed/NCBI
|
|
65
|
Ho AS, Turcan S and Chan TA: Epigenetic
therapy: Use of agents targeting deacetylation and methylation in
cancer management. Onco Targets Ther. 6:223–232. 2013.PubMed/NCBI
|
|
66
|
Wu CC, Chuang HY, Lin CY, et al:
Inhibition of Epstein-Barr virus reactivation in nasopharyngeal
carcinoma cells by dietary sulforaphane. Mol Carcinog. 52:946–958.
2013. View Article : Google Scholar
|
